<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593801</url>
  </required_header>
  <id_info>
    <org_study_id>12008</org_study_id>
    <secondary_id>Hoffmann- La Roche,MF 4481</secondary_id>
    <nct_id>NCT00593801</nct_id>
  </id_info>
  <brief_title>Erythropoietin Treatment in Extremely Low Birth Weight Infants</brief_title>
  <acronym>EPO</acronym>
  <official_title>Multicentre, Blinded, Randomised, Controlled Study on the Efficacy and Safety of Early or Late Epoetin Beta Treatment in Premature Infants (500- 999g Birth Weight)for Prevention or Treatment of Anaemia of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital at the Bult Hannover, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Aachen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Koeln, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Dortmund, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Antoine Beclere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Olga Hospital Stuttgart, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To investigate whether recombinant EPO reduces the need for transfusion in
      extremely low birth weight (ELBW) infants and to determine the optimal time for treatment.

      The concentrations of trace elements and of antioxidant enzymes were investigated in all
      patients, too.

      Study population: 219 patient randomized into 3 groups
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: Blinded , multicenter trial, ELBW infants were randomized on day 3 to one of 3
      groups: early EPO group (rhEPO from the first week for 9 weeks , n= 74), late rhEPO group
      (rhWEPO from the fourth week for 6 weeks, n=74), or control group (no rhEPO, n= 71). All
      infants received enteral iron (3-9 mg/kg/day) from the first week. The rhEPO ß dose was 750
      IU/kg/week. Success was defined as no transfusion and hematocrit levels never below 30%.

      The concentrations of trace elements and of antioxidant enzymes were investigated in all
      patients, too. Clinical and nutritional data were recorded prospectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">June 1999</completion_date>
  <primary_completion_date type="Actual">June 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transfusion need</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentrations of trace elements and antioxidant enzymes in the blood</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Infant, Low Birth Weight</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>2: late rhEPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>late EPO treatment from the fourth week for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: no EPO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group, no EPO treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1: early rhEPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>early rhEPO treatment from the first week until 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
    <description>250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day</description>
    <arm_group_label>1: early rhEPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
    <description>250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day</description>
    <arm_group_label>2: late rhEPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Extremely low birth weight infants

        Exclusion Criteria:

          -  Cyanotic heart disease

          -  Major congenital malformation requiring surgery

          -  Gestational age &gt; 30 weeks

          -  Administration of an investigational drug during pregnancy

          -  Lack of parental consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Obladen, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Berlin, University Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Neonatolgy Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>January 4, 2008</last_update_submitted>
  <last_update_submitted_qc>January 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Michael Obladen, former Head of the Dpt. of Neonatology Charité Berlin</name_title>
    <organization>University Medicine Berlin, Charité</organization>
  </responsible_party>
  <keyword>extremely low birth weight infants</keyword>
  <keyword>transfusion need</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>trace elements</keyword>
  <keyword>antioxidant enzymes</keyword>
  <keyword>reduction of the transfusion need by EPO treatment</keyword>
  <keyword>trace elements and antioxidant enzymes in blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

